ALSA Ventures is a London-based international life science investor focused on novel therapeutics. They believe that European innovation in life sciences has the power to create valuable businesses with global impact, coupled with a promising investment market opportunity in Europe. The firm is focused on being a Europe-focused biotechnology fund manager. Their investment approach centers around therapeutics, seeking novel drugs and modalities across a wide variety of disease areas. ALSA Ventures invests across the entire spectrum of drug development, demonstrating comfort in both company formation and participating in syndicates alongside co-investors. The firm aims to build ambitious science-led companies and NewCos around differentiated assets, requiring a wide aperture for talent and ideas, disciplined decision-making, and an ecosystem that allocates capital efficiently. This aligns with their decision to join the Investing in Women Code, which encourages measurable improvements in access to finance and strengthens data-driven accountability across the investment landscape. ALSA Ventures aims to make their engagement with founders consistent, professional, and transparent, which involves clear routes to initial evaluation and feedback, disciplined processes designed to reduce avoidable friction, and a commitment to ongoing review of how their practices affect access to capital.
Bevorzugte Reifephase für die erste Finanzierung.
Novel therapeutics, biotechnology, life sciences, drug development
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
